Table 2. Variables at baseline, immediate, 4 weeks after treatment in patient in Li-ESWT and placebo.

Variable		Baseline	F/U (immediately)	F/U (Week 4)
NIH-CPSI total
	Li-ESWT	27.1±4.8	17.5±4.1*	16.1±4.2*
	Placebo	24.5±5.9	23.8±3.9	23.6±3.1
	p-value for between group	0.478	0.003	0.002
NIH-CPSI pain
	Li-ESWT	13.0±3.6	7.5±3.7*	7.1±5.0*
	Placebo	11.9±3.3	11.8±4.1	11.4±4.5
	p-value for between group	0.375	0.006	0.02
NIH-CPSI urinary
	Li-ESWT	5.0±3.2	3.6±2.9*	3.3±3.1*
	Placebo	3.9±2.7	3.7±3.2	4.1±3.2
	p-value for between group	0.434	0.849	0.081
NIH-CPSI QoL
	Li-ESWT	9.1±2.2	6.4±2.5*	5.7±2.3*
	Placebo	8.7±2.2	8.3±2.3	8.1±2.1
	p-value for between group	0.618	0.042	0.001
IIEF-EF
	Li-ESWT Changes of NIH-CPSI	11.3±10.7	15.1±10.1*	14.0±11.4*
	Placebo total score from baseline	20.3±9.6	20.3±10.0	17.2±11.3
	p-value for between group	0.023	0.043	0.019
VAS
	Li-ESWT	6.5±2.5	2.9±1.6*	2.7±1.9*
	Placebo	5.8±1.9	5.1±2.2	5.3±2.3
	p-value for between group	0.556	0.005	0.002
PSA
	Li-ESWT	1.03±0.83	-	0.99±0.75
	Placebo	0.81±0.59	-	0.81±0.62
	p-value for between group	0.507	-	0.589

Li-ESWT: low-intensity extracorporeal shockwave therapy, F/U: follow-up, NIH-CPSI: National Institutes of Health-chronic prostatitis symptom index, QoL: quality of life, IPSS: International Prostate Symptom Score, IIEF-EF: International Index of Erectile Function-Erectile Function, VAS: Visual Analogue Scale, PSA: prostate specific antigen, −: not available.

^*p<0.05 compared to baseline.